Introduction And Microbiology
- Meningococcal disease is a life-threatening illness caused by Neisseria meningitidis, representing the leading cause of bacterial meningitis in older children and adolescents globally.
- Neisseria meningitidis is a fastidious, Gram-negative, aerobic, oxidase-positive, and catalase-positive diplococcus classically appearing kidney-bean shaped.
- Optimal growth strictly requires enriched media like chocolate agar or blood agar in an atmosphere of 3% to 5% carbon dioxide.
- The organism oxidizes both glucose and maltose, differentiating it from Neisseria gonorrhoeae, which oxidizes only glucose.
Virulence Factors
| Virulence Factor | Mechanism And Clinical Impact |
|---|---|
| Polysaccharide Capsule | • Serves as the primary virulence factor by inhibiting phagocytosis and complement-mediated lysis. • Classification into 12 serogroups is based on capsular composition, with serogroups A, B, C, W, X, and Y causing almost all invasive disease. |
| Endotoxin (Lipooligosaccharide) | Triggers a massive cytokine storm (Tumor Necrosis Factor-alpha, Interleukin-1, Interleukin-6) resulting in septic shock, capillary leak, and profound coagulopathy. |
| Pili And Adhesins (Opa, Opc) | Mediate direct attachment to nasopharyngeal epithelial cells. |
| IgA1 Protease | Cleaves secretory IgA, facilitating mucosal colonization. |
Epidemiology And Pathogenesis
- The human nasopharynx remains the sole natural reservoir, with transmission occurring strictly via direct contact with respiratory droplets or saliva.
- Asymptomatic carriage peaks in adolescents and young adults (up to 25% to 30%), who serve as the primary reservoir for transmission.
- High-risk host factors include
- functional or anatomic asplenia,
- HIV infection,
- the use of eculizumab, and
- specific terminal complement pathway defects (C5–C9) or properdin deficiency, which increase disease risk up to 600-fold.
- Pathogenesis involves mucosal colonization, transcytosis across the epithelium into the bloodstream, and rapid multiplication shielded by the capsule.
- Release of outer membrane vesicles containing Lipooligosaccharide precipitates widespread endothelial injury, disseminated intravascular coagulation, thrombosis of small vessels, and purpura fulminans.
Clinical Manifestations
| Clinical Syndrome | Key Clinical Features |
|---|---|
| Meningococcemia (Septicemia) | Most severe form characterized by rapid progression. Early symptoms include fever, flu-like myalgia, and severe leg pain (a critical early red flag). A blanching maculopapular rash rapidly evolves into non-blanching petechiae and purpura fulminans. |
| Meningitis | Occurs in 30% to 50% of invasive cases. Presents with fever, headache, photophobia, and nuchal rigidity. Infants manifest subtle signs including a bulging fontanelle, high-pitched cry, and irritability. |
| Chronic Meningococcemia | A rare form featuring intermittent fever, rash, and arthralgia lasting weeks to months. |
| Focal Infections | May present as primary or secondary pneumonia, septic or immune-complex arthritis, and purulent pericarditis. |
Diagnostic Evaluation
- Treatment must never be delayed for diagnostic testing in suspected cases.
- Cerebrospinal Fluid Analysis: Reveals polymorphonuclear pleocytosis, elevated protein exceeding 100 mg/dL, and low glucose below 40 mg/dL. Gram stain demonstrates Gram-negative diplococci in 75% to 90% of untreated cases.
- Blood And Skin Cultures: Blood culture is positive in 50% to 70% of untreated cases but drops below 5% following antibiotic administration. Gram stain and culture of petechiae or purpura aspirates can remain diagnostic post-antibiotics.
- Molecular Testing: Polymerase Chain Reaction targeting meningococcal DNA (e.g., ctrA gene) in blood or cerebrospinal fluid is highly sensitive and remains positive for days after antibiotic treatment.
Management Protocol
Antimicrobial Therapy
| Antibiotic Agent | Dosage And Role |
|---|---|
| Ceftriaxone | 100 mg/kg/day intravenously once daily or divided every 12 hours (maximum 4g). Serves as the drug of choice because it simultaneously eradicates nasopharyngeal carriage. |
| Cefotaxime | 200 to 300 mg/kg/day intravenously divided every 6 hours. Represents a preferred alternative in neonates. |
| Penicillin G | 300,000 to 400,000 U/kg/day intravenously divided every 4 to 6 hours for susceptible strains. Requires Rifampin prophylaxis before discharge because it fails to eradicate carriage. |
Supportive And Adjunctive Care
- Hemodynamic Resuscitation: Aggressive fluid resuscitation utilizing isotonic crystalloids is essential to manage hypovolemia from capillary leak.
- Inotropic Support: Vasoactive agents such as epinephrine or dopamine are frequently required to manage myocardial depression and pathological vasodilation.
- Adjunctive Corticosteroids: Dexamethasone administered at 0.15 mg/kg every 6 hours is generally recommended if given before or with the first dose of antibiotics to reduce neurologic sequelae like hearing loss.
Prevention And Prophylaxis
Chemoprophylaxis
- Indicated strictly for close contacts of the index case within the 7 days preceding illness, administered ideally within 24 hours.
- Rifampin: Drug of choice for children, administered orally every 12 hours for 2 days (10 mg/kg for children older than 1 month; 5 mg/kg for neonates).
- Ceftriaxone: Single intramuscular dose serving as the drug of choice for pregnant women.
- Ciprofloxacin: Single oral dose for adults and children if no local resistance is reported.
Immunoprophylaxis
- Conjugate Vaccines (MenACWY): Induce T-cell dependent immunity, immune memory, and herd immunity by reducing carriage. Routinely administered at 11 to 12 years with a booster at 16 years.
- Serogroup B Vaccines (MenB): Recombinant protein vaccines recommended for high-risk groups older than 10 years and during outbreaks.
Prognosis
- Case fatality remains high at 5% to 10% despite prompt treatment.
- Severe sequelae afflict 11% to 19% of survivors, manifesting as sensorineural hearing loss, limb amputations secondary to purpura fulminans, skin scarring, and permanent neurologic deficits.
- Poor prognostic indicators include shock, purpura fulminans, coma, low white blood cell count, and thrombocytopenia.